Literature DB >> 12349914

Dosimetry for ocular proton beam therapy at the Harvard Cyclotron Laboratory based on the ICRU Report 59.

W D Newhauser1, J Burns, A R Smith.   

Abstract

The Massachusetts General Hospital, the Harvard Cyclotron Laboratory (HCL), and the Massachusetts Eye and Ear Infirmary have treated almost 3000 patients with ocular disease using high-energy external-beam proton radiation therapy since 1975. The absorbed dose standard for ocular proton therapy beams at HCL was based on a fluence measurement with a Faraday cup (FC). A majority of proton therapy centers worldwide, however, use an absorbed dose standard that is based on an ionization chamber (IC) technique. The ion chamber calibration is deduced from a measurement in a reference 60Co photon field together with a calculated correction factor that takes into account differences in a chamber's response in 60Co and proton fields. In this work, we implemented an ionization chamber-based absolute dosimetry system for the HCL ocular beamline based on the recommendations given in Report 59 by the International Commission on Radiation Units and Measurements. Comparative measurements revealed that the FC system yields an absorbed dose to water value that is 1.1% higher than was obtained with the IC system. That difference is small compared with the experimental uncertainties and is clinically insignificant. In June of 1998, we adopted the IC-based method as our standard practice for the ocular beam.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12349914     DOI: 10.1118/1.1487425

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  8 in total

1.  Independent dose per monitor unit review of eight U.S.A. proton treatment facilities.

Authors:  M F Moyers; G S Ibbott; R L Grant; P A Summers; D S Followill
Journal:  Med Phys       Date:  2014-01       Impact factor: 4.071

2.  Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy.

Authors:  Nicholas Koch; Wayne D Newhauser; Uwe Titt; Dan Gombos; Kevin Coombes; George Starkschall
Journal:  Phys Med Biol       Date:  2008-02-25       Impact factor: 3.609

3.  Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams.

Authors:  Wayne D Newhauser; Laura Rechner; Dragan Mirkovic; Pablo Yepes; Nicholas C Koch; Uwe Titt; Jonas D Fontenot; Rui Zhang
Journal:  Radiat Meas       Date:  2013-11-01       Impact factor: 1.898

Review 4.  The physics of proton therapy.

Authors:  Wayne D Newhauser; Rui Zhang
Journal:  Phys Med Biol       Date:  2015-03-24       Impact factor: 3.609

5.  Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions.

Authors:  U Titt; N Sahoo; X Ding; Y Zheng; W D Newhauser; X R Zhu; J C Polf; M T Gillin; R Mohan
Journal:  Phys Med Biol       Date:  2008-07-31       Impact factor: 3.609

6.  Monte Carlo simulation of the neutron spectral fluence and dose equivalent for use in shielding a proton therapy vault.

Authors:  Yuanshui Zheng; Wayne Newhauser; Eric Klein; Daniel Low
Journal:  Phys Med Biol       Date:  2009-11-04       Impact factor: 3.609

7.  Development and verification of an analytical algorithm to predict absorbed dose distributions in ocular proton therapy using Monte Carlo simulations.

Authors:  Nicholas C Koch; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-01-14       Impact factor: 3.609

8.  Effects of defining realistic compositions of the ocular melanoma on proton therapy.

Authors:  Sh Keshazare; S F Masoudi; F S Rasouli
Journal:  J Biomed Phys Eng       Date:  2014-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.